This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/domain/vavai/projekt/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F12%3A%230001896%21RIV13-MZ0-65269705/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n5http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n19http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F65269705%3A_____%2F12%3A%230001896%21RIV13-MZ0-65269705
rdf:type
n5:Vysledek skos:Concept
dcterms:description
In a phase II clinical study, pretreated multiple myeloma patients with relapsing or stable disease received autologous anticancer vaccine containing dendritic cells loaded with Id-protein. Patients received a total of 6 vaccine doses intradermally in monthly intervals. No clinical responses were observed. During the follow-up with a median of 33.1 months (range: 11-43 months), the disease remained stable in 7/11 (64%) of patients. Immune responses measured by ELISpot were noted in 3/11 (27%) and DTH skin test for Id-protein was positive in 8/11 (73%) of patients; out of those, 1/11 (9%) and 5/11 (46%), respectively, had preexisting immune response to Id-protein before the vaccination began. Outcomes were compared to those of a control group of 13 patients. A trend to lower cumulative incidence of progression in the vaccinated group was observed at 12 months from the first vaccination (p = 0.099). More patients from the control group compared to vaccinated patients required active anticancer therapy [4/11 (36%) vs. 8/13 (62%)]. Vaccines based on dendritic cells loaded with Id-protein are safe and induce specific immune response in multiple myeloma patients. Our results suggest that the vaccination could stabilize the disease in approximately two-thirds of patients. In a phase II clinical study, pretreated multiple myeloma patients with relapsing or stable disease received autologous anticancer vaccine containing dendritic cells loaded with Id-protein. Patients received a total of 6 vaccine doses intradermally in monthly intervals. No clinical responses were observed. During the follow-up with a median of 33.1 months (range: 11-43 months), the disease remained stable in 7/11 (64%) of patients. Immune responses measured by ELISpot were noted in 3/11 (27%) and DTH skin test for Id-protein was positive in 8/11 (73%) of patients; out of those, 1/11 (9%) and 5/11 (46%), respectively, had preexisting immune response to Id-protein before the vaccination began. Outcomes were compared to those of a control group of 13 patients. A trend to lower cumulative incidence of progression in the vaccinated group was observed at 12 months from the first vaccination (p = 0.099). More patients from the control group compared to vaccinated patients required active anticancer therapy [4/11 (36%) vs. 8/13 (62%)]. Vaccines based on dendritic cells loaded with Id-protein are safe and induce specific immune response in multiple myeloma patients. Our results suggest that the vaccination could stabilize the disease in approximately two-thirds of patients.
dcterms:title
Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results
skos:prefLabel
Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results
skos:notation
RIV/65269705:_____/12:#0001896!RIV13-MZ0-65269705
n5:predkladatel
n16:ico%3A65269705
n3:aktivita
n4:P
n3:aktivity
P(2B06058), P(LC06027), P(NR8945), P(NR9225), P(NS9871)
n3:cisloPeriodika
4
n3:dodaniDat
n8:2013
n3:domaciTvurceVysledku
n7:1873172 n7:1765272 n7:9622748 n7:4954130 n7:1447963 n7:5551579 n7:1285815 n7:7227086 n7:9685596
n3:druhVysledku
n12:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
133521
n3:idVysledku
RIV/65269705:_____/12:#0001896
n3:jazykVysledku
n10:eng
n3:klicovaSlova
multiple myeloma
n3:klicoveSlovo
n6:multiple%20myeloma
n3:kodStatuVydavatele
SK - Slovenská republika
n3:kontrolniKodProRIV
[A552443E595B]
n3:nazevZdroje
Neoplasma
n3:obor
n18:FD
n3:pocetDomacichTvurcuVysledku
9
n3:pocetTvurcuVysledku
10
n3:projekt
n13:NR9225 n13:NR8945 n13:LC06027 n13:NS9871 n13:2B06058
n3:rokUplatneniVysledku
n8:2012
n3:svazekPeriodika
59
n3:tvurceVysledku
Zahradová, Lenka Křivanová, Andrea Kovářová Říhová, Lucie Pour, Luděk Očadlíková, Darina Krejčí, Marta Adam, Zdeněk Sandecká, Viera Hájek, Roman
n3:wos
000305499900012
s:issn
0028-2685
s:numberOfPages
10
n19:doi
10.4149/neo_2012_057